Building the business case

Many people these days acknowledge that molecular methods for rapid AMR screening are faster and have a higher accuracy than conventional culture-based methods.

Some people still feel that molecular screening could be expensive compared to phenotypical screening. Taking into account the specific situation of your hospital the contrary could be true however. Rapid screening for CPO, ESBL and other resistance mechanisms is more cost effective than you may think and can lead to net cost savings for your hospital.

Below you find the key messages to consider when moving into rapid screening.

Would you like to know more about building a convincing business case for rapid AMR screening in your situation? Contact us>>